Patent for Retinal Cells | LCTX Message Board Posts


Lineage Cell Therapeutics

  LCTX website

LCTX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  256 of 261  at  10/11/2023 11:11:30 AM  by

futurequest


Patent for Retinal Cells

 Oct. 11, 2023-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,746,324, entitled “Large Scale Production of Retinal Pigment Epithelial Cells”. The patent, which has been exclusively licensed to Lineage, has an expected expiration date of July 28, 2036. RG6501 (OpRegen®) is a suspension of human allogeneic RPE cells currently in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 2  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...